Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Motivational interviewing vs control Drug abuse Self reported use of marijuana · patients with Improving outcomes in youth living with HIV Motivational interviewing for improving outcomes in youth living with HIV (2012) · Cochrane | OR 1.23 [0.57, 2.63] | 1 study · 143 participants | Moderate |
Motivational interviewing vs control Alcohol abuse Self reported alcohol use · patients with Improving outcomes in youth living with HIV Motivational interviewing for improving outcomes in youth living with HIV (2012) · Cochrane | OR 0.58 [0.3, 1.12] | 1 study · 143 participants | Moderate |
Multivitamins vs no multivitamins Birthweight Standard beam balance to nearest 10g · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 800 participants | Moderate |
Intervention NR Preterm < 37 wks · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.1 [0.7, 1.76] | 1 study · 366 participants | Moderate |
Intervention NR Perinatal death · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.36 [0.75, 2.47] | 1 study · 397 participants | Moderate |
Intervention NR Birth weight (g) Standard balance beam to within 10g after birth · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 358 participants | Moderate |
Intervention NR Mean change in Log10viral load at 6 weeks postpartum PCR Roche Amplicor version 1.5kit · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 100 participants | Low |
Intervention NR Overall weight gain during pregnancy Calibrated balance beam scale to the nearest 100g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 376 participants | Moderate |
Intervention NR Birth weight Standard mechanical scale to nearest 50g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 842 participants | Moderate |
Intervention NR Low birth weight < 2500 g Standard mechanical scale to nearest 50g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.68 [0.47, 0.98] | 1 study · 842 participants | Moderate |
Intervention NR Preterm birth < 37 weeks Gestational age was based on date of last menstrual period and was obtained at baseline · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.01 [0.74, 1.37] | 1 study · 842 participants | Moderate |
Intervention NR Perinatal death Death between 28 weeks gestation and 1 week after delivery · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.35 [0.85, 2.13] | 1 study · 881 participants | Moderate |
Intervention NR Progression to Hb < 8.6g/dL AcT Diff II Analyzer (Beckman Coulter) · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.63 [0.23, 1.73] | 1 study · 467 participants | Moderate |
Multivitamins vs no multivitamins Birth weight < 2500g Standard beam balance to nearest 10g · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.55 [0.38, 0.81] | 1 study · 800 participants | Moderate |
Intervention NR Change in viral load · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 438 participants | Ungraded |
Intervention NR Maternal mortality · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1 [0.51, 1.97] | 1 study · 913 participants | Moderate |
Intervention NR Birth weight (grammes) Standard balance beam to nearest 10g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 1000 participants | Moderate |
Intervention NR Birth weight < 2 500g Standard balance beam to nearest 10g · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.13 [0.79, 1.61] | 1 study · 1000 participants | Moderate |
Intervention NR Preterm birth < 37 weeks Gestational age based on the date of last menstrual period · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.04 [0.81, 1.35] | 1 study · 1030 participants | Moderate |
Intervention NR Small‐for‐gestational‐age Gestational age based on last menstrual period · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.24 [0.9, 1.71] | 1 study · 972 participants | Moderate |
Intervention NR Perinatal death · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.77 [0.48, 1.23] | 1 study · 1115 participants | Moderate |
Intervention NR Haemoglobin < 11g/dL within 10 weeks of delivery (dichotomous) CBC5 Coulter Counter · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.94 [0.67, 1.32] | 1 study · 272 participants | Low |
Intervention NR Mean viral load (log10) within 10 weeks of delivery Roche Amplicor HIV‐1 monitor test version 1.5 assay · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 174 participants | Low |
Multivitamins vs no multivitamins Preterm birth < 37 weeks Gestational age was determined using date of last menstrual period obtained at randomisation · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.86 [0.68, 1.1] | 1 study · 888 participants | Moderate |
Multivitamins vs no multivitamins Small‐for‐gestational‐age Gestational age was determined using date of last menstrual period obtained at randomisation · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.57 [0.4, 0.83] | 1 study · 768 participants | Moderate |
Multivitamins vs no multivitamins Foetal death (stillbirth and miscarriage) · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 0.61 [0.39, 0.94] | 1 study · 1021 participants | Moderate |
Multivitamins vs no multivitamins Maternal change in mean Haemoglobin from baseline to 6 weeks post‐partum CBC5 Coulter Counter · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 1021 participants | Moderate |
Multivitamins vs no multivitamins Maternal change in mean CD4 from baseline to 6 weeks post‐partum FACScount system (Becton‐Dickinson) · Pregnant and lactating women with HIV Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 516 participants | Low |
Intervention NR Mean change in Haemoglobin at 6 weeks post partum CBC5 Coulter Counter · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | no estimate extracted | 1 study · 357 participants | Moderate |
Intervention NR Low birth weight < 2500g Standard balance beam to within 10g after birth · Pregnant women with HIV infection Micronutrient supplementation in pregnant women with HIV infection (2012) · Cochrane | RR 1.06 [0.58, 1.93] | 1 study · 358 participants | Moderate |
Mobile phone text messages vs standard care Viral load suppression at 52 weeks · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.83 [0.69, 0.99] | 1 study · 538 participants | High |
Intervention NR ART adherence at 48 weeks: Weekly vs. daily messages (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.79 [0.64, 0.99] | 1 study · 289 participants | Low |
Intervention NR ART adherence at 48 weeks: Short vs. long messages (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 1.01 [0.81, 1.25] | 1 study · 289 participants | Low |
Intervention NR Very few events. · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Mobile phone text messages vs standard care ART adherence at 48‐52 weeks: Text messages vs. standard care (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.82 [0.72, 0.94] | 2 studies · 966 participants | High |
Mobile phone text messages vs standard care ART adherence at 48‐52 weeks: Weekly text messages vs. standard care (overall) · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.78 [0.68, 0.89] | 2 studies · 898 participants | High |
Mobile phone text messages vs standard care ART adherence at 48‐52 weeks: Short weekly messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.77 [0.66, 0.9] | 2 studies · 750 participants | High |
Mobile phone text messages vs standard care ART adherence at 48 weeks: Long weekly messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.79 [0.6, 1.04] | 1 study · 213 participants | Low |
Mobile phone text messages vs standard care ART adherence at 48 weeks: Short daily messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 1 [0.79, 1.27] | 1 study · 209 participants | Low |
Mobile phone text messages vs standard care ART adherence at 48 weeks: Long daily messages vs. standard care · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.98 [0.77, 1.24] | 1 study · 211 participants | Low |
Mobile phone text messages vs standard care Very few events. · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Intervention NR ART adherence at 48 weeks: Short weekly messages vs. long weekly messages · Patients with HIV infection, on ART Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (2012) · Cochrane | RR 0.98 [0.7, 1.39] | 1 study · 147 participants | Low |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL Global state: clinically important change in global state needing additional medication ‐ chlorpromazine · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | OR 0.19 [0.05, 0.71] | 1 study · 45 participants | Very low |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL Mental state and behaviour: clinically important change in general mental state and behaviour · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | no estimate extracted | 1 study · 45 participants | Ungraded |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL Adverse effects/events: incidence of adverse effects/events · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL Service outcomes: hospital admission · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL General functioning: Poor social functioning ‐ modified Cooper's ratings5,6 · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | RR 1.33 [0.91, 1.96] | 1 study · 45 participants | Very low |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL Satisfaction with treatment: satisfaction with care for recipients of care or careers · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
α‐FLUPENTHIXOL vs PLACEBO or β‐FLUPENTHIXOL Economic outcomes: direct costs · patients with schizophrenia Flupenthixol versus placebo for schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Early routine ERCP strategy vs early conservative management with or without delayed or selective ERCP strategy All‐cause mortality, ITT analysis · patients with unselected patients with acute gallstone pancreatitis Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management… (2012) · Cochrane | RR 0.74 [0.18, 3.03] | 5 studies · 644 participants | Low |